Plus Therapeutics Reports Satisfactory Equity, Avoids Nasdaq Delisting

Plus Therapeutics reported a stockholders' equity of $3 million as of June 30, 2025, meeting Nasdaq's Listing Rule 5550(b)(1). The company had previously notified of not satisfying the equity rule as of March 31, 2025. With a mandatory panel monitor through March 6, 2026, the delist determination has been issued.

Houston, Aug. 15, 2025 — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has successfully addressed its Nasdaq listing compliance concerns. The company reported stockholders' equity of $3 million as of June 30, 2025, exceeding the minimum requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).

This development follows a period of non-compliance identified on June 3, 2025, which led to a hearing before the Nasdaq Hearings Panel on July 15, 2025. The Panel granted Plus an extension to demonstrate compliance, and the company's recent Form 10-Q filing on August 14, 2025, confirms its return to compliance with the Equity Rule.

Plus Therapeutics regains Nasdaq compliance by exceeding minimum equity requirements, avoiding potential delisting. The company had previously been notified that it no longer satisfied the Equity Rule as of March 31, 2025, leading to a delist determination. However, the company successfully requested a hearing and was granted an extension to evidence compliance with the Equity Rule. The company now awaits official confirmation from Nasdaq that it has satisfied the equity requirement condition.

Maintaining Nasdaq listing status is crucial for public biotech companies like Plus Therapeutics. A delisting would have severely restricted access to capital markets, reduced share liquidity, diminished institutional investor interest, and potentially triggered defaults on financial agreements. For clinical-stage companies without consistent revenue streams, maintaining market access is particularly vital for ongoing financing of research and development activities.

While the company has resolved this immediate compliance concern, investors should note that Plus remains under a Mandatory Panel Monitor through March 2026, indicating ongoing regulatory scrutiny of its financial position. The company now awaits official confirmation from Nasdaq that it has satisfied the equity requirement condition.

References:
[1] https://www.globenewswire.com/news-release/2025/08/15/3134170/0/en/Plus-Therapeutics-Reports-Stockholders-Equity-in-Excess-of-2-5-million-in-Compliance-with-Nasdaq-Equity-Requirements.html
[2] https://www.stocktitan.net/news/PSTV/plus-therapeutics-reports-stockholders-equity-in-excess-of-2-5-5uahvgmy8by2.html